Merck KGaA
General ticker "MKGAF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $59.5B (TTM average)
Merck KGaA follows the US Stock Market performance with the rate: 15.7%.
Estimated limits based on current volatility of 3.0%: low 147.98$, high 157.07$
Factors to consider:
- Company pays dividends (annually): last record date 2025-04-29, amount 2.50$ (Y1.65%)
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [111.55$, 176.63$]
- 2025-12-31 to 2026-12-31 estimated range: [113.61$, 178.47$]
Financial Metrics affecting the MKGAF estimates:
- Negative: with PPE of 19.6 at the end of fiscal year the price was high
- Positive: 7.61 < Operating profit margin, % of 17.23
- Positive: 42.77 < Shareholder equity ratio, % of 58.01 <= 64.37
- Positive: 6.66 < Operating cash flow per share per price, % of 7.58
- Positive: 1.84 < Return on assets ratio (scaled to [-100,100]) of 5.11
- Positive: Inventory ratio change, % of 0.20 <= 0.79
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0.48 <= 0.73
Short-term MKGAF quotes
Long-term MKGAF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €22,232.00MM | €20,993.00MM | €21,156.00MM |
| Operating Expenses | €17,758.00MM | €17,384.00MM | €17,511.00MM |
| Operating Income | €4,474.00MM | €3,609.00MM | €3,645.00MM |
| Non-Operating Income | €-187.00MM | €-125.00MM | €-109.00MM |
| Interest Expense | €207.63MM | €272.00MM | €292.00MM |
| R&D Expense | €2,521.00MM | €2,445.00MM | €2,279.00MM |
| Income(Loss) | €4,287.00MM | €3,484.00MM | €3,536.00MM |
| Taxes | €948.00MM | €650.00MM | €751.00MM |
| Profit(Loss)* | €3,326.00MM | €2,824.00MM | €2,777.00MM |
| Stockholders Equity | €25,927.00MM | €26,680.00MM | €29,912.00MM |
| Inventory | €4,632.00MM | €4,637.00MM | €4,484.00MM |
| Assets | €48,526.00MM | €48,495.00MM | €51,567.00MM |
| Operating Cash Flow | €4,259.00MM | €3,784.00MM | €4,586.00MM |
| Capital expenditure | €1,806.00MM | €2,023.00MM | €2,184.00MM |
| Investing Cash Flow | €-2,743.00MM | €-1,892.00MM | €-3,050.00MM |
| Financing Cash Flow | €-1,555.00MM | €-1,732.00MM | €-985.00MM |
| Earnings Per Share** | €7.65 | €6.49 | €6.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.